A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

NCT ID: NCT02156349

Last Updated: 2017-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

558 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-14

Study Completion Date

2017-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Outcome of both studies (RD001732 and RD001231) will be integrated and additionally reported as PDM-ProValue study program (Integrated Personalized Diabetes Management) due to the high similarity in study characteristics, design and study results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type II Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.

Group Type OTHER

Accu-Chek Smart Pix readout Device

Intervention Type DEVICE

Smartpix device for data upload out of blood glucose meter devices

Intervention group

Patients are treated according to the concept "Integrated personalized diabetes management".

Group Type OTHER

Accu-Chek Smart Pix Software

Intervention Type DEVICE

Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Accu-Chek Smart Pix Software

Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

Intervention Type DEVICE

Accu-Chek Smart Pix readout Device

Smartpix device for data upload out of blood glucose meter devices

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* existence of a signed Informed Consent form (before any study procedure)
* diagnosed Type 2 diabetes mellitus
* age ≥18 years
* insulin therapy for ≥6 months: BOT, SIT, CT or ICT
* HbA1c ≥7.5% (≥ 58,47 mmol/mol respectively), blood withdrawal for measurement in the last 90 days before study visit 1 (patient's inclusion)
* longer-term care (at least for the duration of the 12-month study participation) by the trial site
* insured by the statutory health insurance (GKV) as a compulsory member or voluntarily insured member or as a family co-insured member
* willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written

Exclusion Criteria

* Treatment of diabetes with insulin pump (CSII)
* Methodic and continuous with the use of particular software for processing of SMBG data - by the patient and at visits in the practice by the physician/diabetes educator - in the past 12 months before study participation.presence of terminal renal failure (eGFR \< 15ml/min) / dialysis and/or a loss of sight (visual acuity ≤ 0,05 of the better eye)
* Existing tumor illness (primary tumor/local recurrence/ metastases except Basal Cell Carcinoma) in the past 5 years before study participation newly diagnosed or treated acutely (hormone, chemo- or radiation therapy). Within a tumor free time of \< 5 years Medical Affairs will decide about individual cases
* permanent use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy
* known alcohol and drug abuse and medication abuse
* known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement)
* existing pregnancy, breast-feeding or plan to become pregnant during study participation
* physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently
* dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Roche Diabetes Care

INDUSTRY

Sponsor Role collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Iris Vesper

Role: STUDY_DIRECTOR

Roche Diabetes Care

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Private Practice

Altenstadt, , Germany

Site Status

Internistische Gemeinschaftspraxis

Augsburg, , Germany

Site Status

Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM)

Bad Mergentheim, , Germany

Site Status

Private Practice

Bad Säckingen, , Germany

Site Status

Private Practice

Berlin, , Germany

Site Status

MVZ am Bahnhof Spandau

Berlin, , Germany

Site Status

Gemeinschaftspraxis

Bitburg, , Germany

Site Status

Private Practice

Buxtehude, , Germany

Site Status

Praxis Kugler

Cologne, , Germany

Site Status

Private Practice

Cuxhaven, , Germany

Site Status

Diabetologicum Dresden

Dresden, , Germany

Site Status

Universitätsklinikum Carl Gustav Carus

Dresden, , Germany

Site Status

Gemeinschaftspraxis Schaden

Düsseldorf, , Germany

Site Status

Private Practice

Essen, , Germany

Site Status

Schwerpunktpraxis für Diabetes, Gefäß- und Ernährungsmedizin

Falkensee, , Germany

Site Status

Private Practice

Frankfurt am Main, , Germany

Site Status

Gemeinschaftspraxis

Fulda, , Germany

Site Status

Private Practice

Gelnhausen, , Germany

Site Status

Hausärztliche internistische Gemeinschaftspraxis Giessen

Giessen, , Germany

Site Status

Diabetes- und Gesundheitszentrum Göttingen

Göttingen, , Germany

Site Status

Private Practice

Gummersbach, , Germany

Site Status

Private Practice

Hamburg, , Germany

Site Status

Diabeteszentrum

Hamburg, , Germany

Site Status

Private Practice

Hanau, , Germany

Site Status

Integriertes Diabetiker-Zentrum Hannover

Hanover, , Germany

Site Status

Gemeinschaftspraxis

Herne, , Germany

Site Status

Gemeinschaftspraxis im Altstadt-Carree

Hessen, , Germany

Site Status

Private Practice

Immenhausen, , Germany

Site Status

Universitätsklinikum Jena, Klinik für Innere Medizin III

Jena, , Germany

Site Status

Diabeteszentrum Kassel

Kassel, , Germany

Site Status

Internistische Praxis Lampertheim

Lampertheim, , Germany

Site Status

Private Practice

Lauf (Pegnitz), , Germany

Site Status

Private Practice

Laupheim, , Germany

Site Status

Private Practice

Lingen, , Germany

Site Status

Diabetes-Zentrum Neustadt

Neustadt am Rübenberge, , Germany

Site Status

Diabetologische Schwerpunktpraxis

Nordrhein-Westfalen, , Germany

Site Status

Private Practice

Offenbach, , Germany

Site Status

Diabetes Praxis Oranienburg

Oranienburg, , Germany

Site Status

Arztpraxis fur Allg-Med

Pirna, , Germany

Site Status

Private Practice

Porta Westfalica, , Germany

Site Status

Private Practice

Rehburg-Loccum, , Germany

Site Status

Gemeinschaftspraxis

Rhaunen, , Germany

Site Status

Pivate Practice

Rüsselsheim am Main, , Germany

Site Status

Ambulanzzentrum Schweinfurt

Schweinfurt, , Germany

Site Status

Versdias Gmbh

Sulzbach-Rosenberg, , Germany

Site Status

Private Practice

Trier, , Germany

Site Status

Gemeinschaftspraxis am Bärenplatz

Villingen-Schwenningen, , Germany

Site Status

Diabetolog. Schwerpunktpraxis

Wiesbaden, , Germany

Site Status

Internistische Praxis

Zierenberg, , Germany

Site Status

Arztpraxis Zossen / Dabendorf

Zossen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD001732

Identifier Type: -

Identifier Source: org_study_id